Capricor Therapeutics IncNASDAQ:CAPR
- LAST PRICE5.2850
- TODAY'S CHANGE (%)-0.0450 (-0.8443%)
- Bid / Lots5.2500/ 3
- Ask / Lots5.2800/ 7
- Open / Previous Close5.2800 / 5.3300
- Day Range
- 52 Week Range
- Volume36,643
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CAPR |
|---|---|---|
| 09:32 ET | 567 | 5.2837 |
| 09:38 ET | 6998 | 5.3343 |
| 09:43 ET | 100 | 5.33 |
| 09:45 ET | 100 | 5.3394 |
| 09:48 ET | 245 | 5.39 |
| 09:50 ET | 800 | 5.365 |
| 09:56 ET | 6100 | 5.29 |
| 10:01 ET | 881 | 5.29 |
| 10:08 ET | 100 | 5.28 |
| 10:10 ET | 100 | 5.26 |
| 10:12 ET | 3200 | 5.24 |
| 10:14 ET | 600 | 5.238 |
| 10:15 ET | 241 | 5.23 |
| 10:19 ET | 4360 | 5.26 |
| 10:30 ET | 250 | 5.2746 |
| 10:32 ET | 736 | 5.285 |
Apr 25, 2024
DJ Capricor Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co., from 7:38AM ET on Thursday Apr 25, 2024 by Dow Jones
7:38AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 24, 2024
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy, from 9:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
9:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Capricor Therapeutics Inc | 167.9M | -6.1x | --- |
Cellectis SA | 188.0M | -1.3x | --- |
Mediwound Ltd | 182.4M | -24.5x | --- |
Compugen Ltd | 177.3M | -9.1x | --- |
ProQR Therapeutics NV | 160.7M | -5.2x | --- |
Uniqure NV | 210.0M | -0.7x | --- |
Company Information
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
Contact Information
- Headquarters
- 8840 Wilshire Blvd, 2nd FloorBEVERLY HILLS, CA, United States 90211
- Phone
- 310-358-3200
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Frank Litvack
- President, Chief Executive Officer, Director
- Linda Marban
- Chief Financial Officer
- Anthony Bergmann
- Executive Vice President, General Counsel
- Karen Krasney
- Director
- Paul Auwaerter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $167.9M |
|---|---|
Revenue (TTM) | $25.2M |
Shares Outstanding | 31.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 4.07 |
EPS | $-0.87 |
Book Value | $0.73 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | 6.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -95.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
